Sanofi India reported a weak quarterly performance, with net profit declining 28% YoY to Rs.61.7 crore compared to Rs.91.3 crore in the year-ago quarter.
Revenue also fell 18% YoY to Rs.420 crore, reflecting softness in core pharmaceutical sales.
Operational performance weakened as EBITDA dropped 24% to Rs.90.3 crore, indicating margin pressure during the quarter.
The decline in profitability led to EPS falling 32% YoY to Rs.26.83, though the stock continues to trade at a PE of around 25x.
👉 Power Calls | Breakout Stocks | Coffee Can Portfolio |Â